Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 14/20 | 0.72 |
| ▸ | JAK2 | O60674 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | JAK3 | P52333 | 2/20 | 0.50 |
| ▸ | MARK3 | P27448 | 3/20 | 0.48 |
| ▸ | IKBKE | Q14164 | 3/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | BRSK2 | Q8IWQ3 | 2/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.48 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.48 |
| ▸ | ULK1 | O75385 | 1/20 | 0.48 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.48 |
| ▸ | SIK1 | P57059 | 1/20 | 0.48 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.48 |
| ▸ | MELK | Q14680 | 1/20 | 0.48 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.48 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.48 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.48 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15163458 | 0.90 | TBK1 (0.57) | TBK1JAK2HDAC6JAK3JAK1 | |
| SCHEMBL1285018 | 0.88 | TBK1 (0.63) | TBK1JAK2HDAC6JAK3MARK3 | |
| SCHEMBL1284415 | 0.86 | TBK1 (0.65) | TBK1JAK2HDAC6JAK3MARK3 | |
| SCHEMBL1284538 | 0.85 | TBK1 (0.71) | TBK1MARK3IKBKECDK2BRSK2 | |
| SCHEMBL1284578 | 0.84 | TBK1 (1.00) | TBK1JAK3MARK3IKBKECDK2 | |
| SCHEMBL1284191 | 0.83 | TBK1 (0.68) | TBK1MARK3IKBKECDK2BRSK2 | |
| SCHEMBL1284522 | 0.83 | TBK1 (0.68) | TBK1JAK2MARK3IKBKECDK2 | |
| SCHEMBL3711049 | 0.82 | JAK3 (0.49) | TBK1JAK2HDAC6JAK3AURKB | |
| SCHEMBL1284573 | 0.82 | TBK1 (0.78) | TBK1JAK2HDAC6JAK3MARK3 | |
| SCHEMBL1285026 | 0.82 | TBK1 (0.66) | TBK1MARK3IKBKECDK2BRSK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | claimed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MARK3, MAPK8, CDK8 | TBK1 17/4885JAK2 159/4885HDAC6 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.